We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals

57 hedge funds and large institutions have $79.8M invested in Syndax Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

61.15% more ownership

Funds ownership: 0%61.15% (+61%)

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

27% more funds holding

Funds holding: 4557 (+12)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

55% less capital invested

Capital invested by funds: $176M → $79.8M (-$95.9M)

Holders
57
Holders Change
+12
Holders Change %
+26.67%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
15
Increased
15
Reduced
11
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
$6K -$89.7K -8,189 -91%
Bank of America
52
Bank of America
North Carolina
$5K -$2.2K -201 -24%
MAM
53
Meeder Asset Management
Ohio
$2K +$2.37K +216 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$2K +$2.98K +272 New
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K +$1.06K +97 New
BNP Paribas Financial Markets
56
BNP Paribas Financial Markets
France
$466 -$2.81K -256 -80%
GE
57
General Electric
Ohio
-$726K -47,945 Closed
AA
58
ALPS Advisors
Colorado
-$344K -22,669 Closed
LCM
59
Laurion Capital Management
New York
-$305K -20,091 Closed
Citigroup
60
Citigroup
New York
-$4.16K -380 -99%

SNDX Hedge Fund Activity: Q4 2016 in Review

57 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2016, worth a combined $79.8M — down 55% from $176M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SNDX positions and 3 closed out — a net gain of 12 holders — while 15 added to existing stakes and 11 trimmed.

The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $2.19M. The largest seller was Fidelity Investments, cutting an estimated $6.73M.

  • 57 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2016, up from 45 in Q3 2016.
  • Funds reported $79.8M of Syndax Pharmaceuticals stock for Q4 2016, down 55% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q4 2016 and 3 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2016 was EverPoint Asset Management, an estimated $2.19M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $6.73M sold.

Based on aggregated 13F filings for Q4 2016.